Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06512259 · ClinicalTrials.gov registry record
AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction
A clinical trial of Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy, sponsored by AlloSource.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT06512259 is a study of Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy that is actively recruiting participants, run by AlloSource. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06512259, a study of Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy, is actively recruiting participants, sponsored by AlloSource.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, retrospective study which will be used to describe and evaluate the effectiveness of AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.
Conditions Studied
Interventions
- OTHER AlloMend® Acellular Dermal Matrix allograft
Study Locations (1)
Illinois
- Alan H. Chen Surgical Associates, PC - Joliet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-10-19 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06512259
The ClinicalTrials.gov registry entry for NCT06512259 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AlloSource, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy appearing as the primary indexed condition, and to 1 intervention - of which AlloMend® Acellular Dermal Matrix allograft is the first listed.
NCT06512259 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06512259 about?
NCT06512259 is a clinical study titled "AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction". This is a single-center, retrospective study which will be used to describe and evaluate the effectiveness of AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.
What is the current status of trial NCT06512259?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2023-10-19. Estimated completion is 2026-12-31.
What conditions does trial NCT06512259 study?
This clinical trial studies the following conditions: Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy.
What interventions are being tested in trial NCT06512259?
The interventions under investigation include: AlloMend® Acellular Dermal Matrix allograft (OTHER).
Who is sponsoring clinical trial NCT06512259?
This trial is sponsored by AlloSource, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06512259 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.